Cited by 468Regulation of Appetite and ObesityDiabetes Treatment and ManagementPharmacology and Obesity Treatment

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

Näslund, E, Barkeling, B, King, N, Gutniak, M, Blundell, JE, Holst, JJ, Rössner, S, Hellström, PM·1999·International Journal of Obesity

DOI 10.1038/sj.ijo.0800818

Open this paper in CoChat — free account

Abstract

Background Peripheral administration of glucagon-like peptide-1 (GLP-1) for four hours, to normal weight and obese humans, decreases food intake and suppresses appetite.Objective The aim of this study was to assess the effect of an eight hour infusion of GLP-1 on appetite and energy intake at lunch and dinner in obese subjects.Design Randomised, blinded cross-over design with intravenous infusion of GLP-1 (0.75 pmol x kg(-1) min(-1)) or saline.Subjects Eight obese (body mass index, BMI, 45.5 +/- 2.3 kg/m2) male subjects.Measurements Ad libitum energy intake at lunch (12.00 h) and dinner (16.00 h) after an energy fixed breakfast (2.4 MJ) at 08.00 h. Appetite sensations using visual analogue scales, (VAS) immediately before and after meals and hourly in-between. Blood samples for the analysis of glucose, insulin, C-peptide, GLP-1 and peptide YY. Gastric emptying after breakfast and lunch using a paracetamol absorption technique.Results Hunger ratings were significantly lower with GLP-1 infusion. The summed ad libitum energy intake at lunch and dinner was reduced by 1.7 +/- 0.5 MJ (21 +/- 6%) by GLP-1 infusion (P = 0.01). Gastric emptying was delayed by GLP-1 infusion, and plasma glucose concentrations decreased (baseline: 6.6 +/- 0.35 mmol/L; nadir: 5.3 +/- 0.15 mmol/L). No nausea was recorded during GLP-1 infusion.Conclusions Our results demonstrate that GLP-1 decreases feelings of hunger and reduces energy intake in obese humans. One possible mechanism for this finding might be an increased satiety primarily mediated by gastric vagal afferent signals.

Integrity signals

Registry

Crossref · 10.1038/sj.ijo.0800818

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citation
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916
Self-citation
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R. A., & Schmiegel, W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 834
Self-citation
Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citation
Hamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Attenuated GLP-1 secretion in obesity: cause or consequence
Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V (1996) · Gut · doi:10.1136/gut.38.6.916 · Cited by 394

Show all 31 references

Sorted by citations

The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citation
Gastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216
Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Self-citation
The Glucagon-Like Peptides
Kieffer, T. J., & Habener, J. F. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass
le Roux, C. W., Welbourn, R., Werling, M., Osborne, A., Kokkinos, A., Laurenius, A., Lönroth, H., Fändriks, L., Ghatei, M. A., Bloom, S. R., et al. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e3180caa3e3 · Cited by 741
Neuroendocrine control of food intake
Valassi, E., Scacchi, M., & Cavagnini, F. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.06.004 · Cited by 649
A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7-36) Amide on Ad Libitum Energy Intake in Humans
Verdich, C., Flint, A., Gutzwiller, J., Näslund, E. B., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L., Holst, J. J., & Astrup, A. V. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 657
Self-citation
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 581
Ghrelin, CCK, GLP-1, and PYY(3–36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Biomarkers of satiation and satiety
de Graaf, C., Blom, W. A. M., Smeets, P. A. M., Stafleu, A., & Hendriks, H. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.6.946 · Cited by 539
The incretin system and its role in type 2 diabetes mellitus
Holst, J. J., Vilsboll, T., & Deacon, C. F. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 528
Self-citation
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R. P., Brynes, A. E., Frost, G. S., Seal, L., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 468
Central Control of Body Weight and Appetite
Woods, S. C., & D’Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1630 · Cited by 477
Appetite control
Wynne, K., Stanley, S., McGowan, B. M., & Bloom, S. R. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05866 · Cited by 478
Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats
Cani, P. D., Dewever, C., & Delzenne, N. M. (2004) · British Journal Of Nutrition · doi:10.1079/bjn20041225 · Cited by 458
Gastrointestinal hormones and food intake
Strader, A. D., & Woods, S. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.10.043 · Cited by 461
Incretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 456
Self-citation
The Role of Postprandial Releases of Insulin and Incretin Hormones in Meal-Induced Satiety—Effect of Obesity and Weight Reduction
Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384
Self-citation
Oligofructose Promotes Satiety in Rats Fed a High‐Fat Diet: Involvement of Glucagon‐Like Peptide‐1
Cani, P. D., Neyrinck, A. M., Maton, N., & Delzenne, N. M. (2005) · Obesity Research · doi:10.1038/oby.2005.117 · Cited by 390
Hormonal regulation of food intake
Stanley, S., Wynne, K., McGowan, B., & Bloom, S. (2005) · Physiological Reviews · doi:10.1152/physrev.00015.2004 · Cited by 372
Gastrointestinal hormones regulating appetite
Chaudhri, O. B., Small, C. J., & Bloom, S. R. (2006) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2006.1856 · Cited by 362
Satiation, satiety and their effects on eating behaviour
Benelam, B. (2009) · Nutrition Bulletin · doi:10.1111/j.1467-3010.2009.01753.x · Cited by 366
How Palatable Food Disrupts Appetite Regulation
Erlanson‐Albertsson, C. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_179.x · Cited by 330
Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)
Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D. R., & on behalf of the NN2211-1310 International Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1335 · Cited by 309
Gastrointestinal Satiety Signals I. An overview of gastrointestinal signals that influence food intake
Woods, S. C. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00448.2003 · Cited by 318
Liraglutide for weight management: a critical review of the evidence
Mehta, A., Marso, S. P., & Neeland, I. J. (2017) · Obesity Science & Practice · doi:10.1002/osp4.84 · Cited by 311
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
Näslund, E. B., Bogefors, J., Skogar, S., Grybäck, P., Jacobsson, H., Holst, J. J., & Hellström, P. M. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.3.r910 · Cited by 289
Self-citation
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects
Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
Gastrointestinal mechanisms of satiation for food
Ritter, R. C. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.02.012 · Cited by 272
Systemic Administration of the Long-Acting GLP-1 Derivative NN2211 Induces Lasting and Reversible Weight Loss in Both Normal and Obese Rats
Larsen, P. J., Fledelius, C., Knudsen, L. B., & Tang‐Christensen, M. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2530 · Cited by 259
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Effect of GLP-1 on Gastric Volume, Emptying, Maximum Volume Ingested, and Postprandial Symptoms in Humans
Delgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235
The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes
Harder, H., Nielsen, L., Thi, T. D. T., & Astrup, A. V. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1915 · Cited by 230
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
GLP-1 and energy balance: an integrated model of short-term and long-term control
Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220
Appetite regulation and weight control: the role of gut hormones
Perry, B., & Wang, Y. (2012) · Nutrition and Diabetes · doi:10.1038/nutd.2011.21 · Cited by 229
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intragastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses
Little, T. J., Pilichiewicz, A. N., Russo, A., Phillips, L. K., Jones, K. L., Nauck, M. A., Wishart, J. M., Horowitz, M., & Feinle‐Bisset, C. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2220 · Cited by 214
Additional Protein Intake Limits Weight Regain after Weight Loss in Humans
Lejeune, M. P. G. M., Kovacs, E. M. R., & Westerterp-Plantenga, M. S. (2005) · British Journal of Nutrition · doi:10.1079/bjn20041305 · Cited by 211
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205
The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related Peptides
Abu‐Hamdah, R., Rabiee, A., Meneilly, G. S., Shannon, R. P., Andersen, D. K., & Elahi, D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1296 · Cited by 203
Changes in Gastrointestinal Hormones and Leptin after Roux-en-Y Gastric Bypass Procedure: A Review
Beckman, L. M., Beckman, T. R., & Earthman, C. P. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2009.12.023 · Cited by 197
Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 198
The central GLP-1: implications for food and drug reward
Skibicka, K. P. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00181 · Cited by 188
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
Comparison of Postprandial Profiles of Ghrelin, Active GLP-1, and Total PYY to Meals Varying in Fat and Carbohydrate and Their Association With Hunger and the Phases of Satiety
Gibbons, C., Caudwell, P., Finlayson, G., Webb, D., Hellström, P. M., Näslund, E. B., & Blundell, J. E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3835 · Cited by 201
Self-citation
Modulation by high-fat diets of gastrointestinal function and hormones associated with the regulation of energy intake: implications for the pathophysiology of obesity
Little, T. J., Horowitz, M., & Feinle‐Bisset, C. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.531 · Cited by 184
The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C. P., Vilsbøll, T., Knop, F. K., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00035.2013 · Cited by 189
Self-citation
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
Gautier, J. F., Choukem, S. P., & Girard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73397-4 · Cited by 186
Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
Jensen, L., Helleberg, H., Roffel, A., van Lier, J. J., Bjørnsdottir, I., Pedersen, P. J., Rowe, E., Derving Karsbøl, J., & Pedersen, M. L. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.020 · Cited by 182
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 192
Minireview: Gut Peptides Regulating Satiety
Druce, M. R., Small, C. J., & Bloom, S. R. (2004) · Endocrinology · doi:10.1210/en.2004-0089 · Cited by 177
The Integrative Role of CNS Fuel-Sensing Mechanisms in Energy Balance and Glucose Regulation
Sandoval, D., Cota, D., & Seeley, R. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.120806.095256 · Cited by 178
Effects of exercise intensity on plasma concentrations of appetite-regulating hormones: Potential mechanisms
Hazell, T. J., Islam, H., Townsend, L. K., Schmale, M. S., & Copeland, J. L. (2015) · Appetite · doi:10.1016/j.appet.2015.12.016 · Cited by 188
Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel
Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.443 · Cited by 175
Appetite signaling: From gut peptides and enteric nerves to brain
Näslund, E. B., & Hellström, P. M. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.017 · Cited by 181
Self-citation
Role of the glucagon-like-peptide-1 receptor in the control of energy balance
Hayes, M. R., De Jonghe, B. C., & Kanoski, S. E. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.02.029 · Cited by 173
Unraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
The physiological control of eating: signals, neurons, and networks
Watts, A. G., Kanoski, S. E., Sanchez-Watts, G., & Langhans, W. (2022) · Physiological Reviews · doi:10.1152/physrev.00028.2020 · Cited by 168
Enhancement of intragastric acid stability of a fat emulsion meal delays gastric emptying and increases cholecystokinin release and gallbladder contraction
Marciani, L., Wickham, M. S. J., Singh, G., Bush, D., Pick, B., Cox, E. F., Fillery‐Travis, A., Faulks, R. M., Marsden, C. A., Gowland, P. A., et al. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00452.2006 · Cited by 169
Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis: Incretins, gastric emptying and metabolic control
Edholm, T., Degerblad, M., Grybäck, P., Hilsted, L., Holst, J. J., Jacobsson, H., Efendic, S., Schmidt, P. T., & Hellström, P. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01554.x · Cited by 164
Self-citation
Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes
Gautier, J. F., Fetita, S., Sobngwi, E., & Salaun-Martin, C. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70190-8 · Cited by 164
The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes
Shimoda, M., Kanda, Y., Hamamoto, S., Tawaramoto, K., Hashiramoto, M., Matsuki, M., & Kaku, K. (2011) · Diabetologia · doi:10.1007/s00125-011-2069-9 · Cited by 162
Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
Näslund, E. B., King, N. A., Mansten, S., Adner, N., Holst, J. J., Gutniak, M., & Hellström, P. M. (2004) · British Journal Of Nutrition · doi:10.1079/bjn20031064 · Cited by 160
Self-citation
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13353 · Cited by 157
Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 156
Self-citation
The effects of miglitol on glucagon‐like peptide‐1 secretion and appetite sensations in obese type 2 diabetics
Lee, A., Patrick, P., Wishart, J., Horowitz, M., & Morley, J. E. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00219.x · Cited by 149
Surgical treatment of obesity
Kral, J. G., & Näslund, E. B. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0563 · Cited by 151
Self-citation
Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects
Hellström, P. M., Geliebter, A., Näslund, E. B., Schmidt, P. T., Yahav, E., Hashim, S. A., & Yeomans, M. R. (2004) · British Journal Of Nutrition · doi:10.1079/bjn20041142 · Cited by 156
Self-citation
Energy Expenditure, Satiety, and Plasma Ghrelin, Glucagon-Like Peptide 1, and Peptide Tyrosine-Tyrosine Concentrations following a Single High-Protein Lunch
Smeets, A. J. P. G., Soenen, S., Luscombe‐Marsh, N. D., Ueland, Ø., & Westerterp‐Plantenga, M. S. (2008) · Journal of Nutrition · doi:10.1093/jn/138.4.698 · Cited by 151
Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects
Hlebowicz, J., Hlebowicz, A., Lindstedt, S., Björgell, O., Höglund, P., Holst, J. J., Darwiche, G., & Almér, L. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26807 · Cited by 154
Self-citation
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146
Breakfast Consumption Affects Appetite, Energy Intake, and the Metabolic and Endocrine Responses to Foods Consumed Later in the Day in Male Habitual Breakfast Eaters
Astbury, N. M., Taylor, M. A., & Macdonald, I. A. (2011) · Journal of Nutrition · doi:10.3945/jn.110.128645 · Cited by 156
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
Neumiller, J. J. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09078 · Cited by 144
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142
Self-citation
Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration
Duarte, A. I., Candeias, E., Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Plácido, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.008 · Cited by 149
Pharmacological management of appetite expression in obesity
Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C., & Harrold, J. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.19 · Cited by 142
Self-citation
Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association
El‐Boghdadly, K., Dhesi, J., Fabb, P., Levy, N., Lobo, D. N., McKechnie, A., Mustafa, O., Newland‐Jones, P., Patel, A., Pournaras, D. J., et al. (2025) · Anaesthesia · doi:10.1111/anae.16541 · Cited by 147
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Reproducibility and power of ad libitum energy intake assessed by repeated single meals
Gregersen, N. T., Flint, A., Bitz, C., Blundell, J. E., Raben, A., & Astrup, A. V. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.5.1277 · Cited by 140
Self-citation
Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects
Adam, T. C., & Westerterp‐Plantenga, M. S. (2005) · British Journal Of Nutrition · doi:10.1079/bjn20041335 · Cited by 134
Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential
Holst, J. J. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(99)00157-5 · Cited by 129
Self-citation
Bariatric surgery, bone loss, obesity and possible mechanisms
Brzozowska, M. M., Sainsbury, A., Eisman, J. A., Baldock, P. A., & Center, J. R. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01050.x · Cited by 128
Diet, Food Intake, and Disturbed Physiology in the Pathogenesis of Symptoms in Functional Dyspepsia
Feinle‐Bisset, C., Vozzo, R., Horowitz, M., & Talley, N. J. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04003.x · Cited by 123
The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans
Flint, A., Raben, A., Jf, R., Holst, J. J., & Astrup, A. V. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801126 · Cited by 121
Self-citation
Dietary Fiber in the Prevention and Treatment of Metabolic Syndrome: A Review
Aleixandre, A., & Miguel, M. (2008) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390701761886 · Cited by 122
The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials
Aldawsari, M., Almadani, F. A., Almuhammadi, N., Algabsani, S., Alamro, Y., & Aldhwayan, M. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s387116 · Cited by 115
Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety
Schmidt, P. T., Näslund, E. B., Grybäck, P., Jacobsson, H., Hartmann, B., Holst, J. J., & Hellström, P. M. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00175-7 · Cited by 114
Self-citation
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
Ansar, S., Koška, J., & Reaven, P. D. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-61 · Cited by 115
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Pratley, R. E., & Gilbert, M. P. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 112
The Glucagon‐Like Peptides
Brubaker, P. L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1317.006 · Cited by 118
A functional neuroimaging review of obesity, appetitive hormones and ingestive behavior
Burger, K. S., & Berner, L. A. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.04.025 · Cited by 110
GLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110

Authors: Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P.
Affiliations: Danderyds sjukhus (SE)
University of Leeds (GB)
ORCID: Näslund, E
Rössner, S
Venue: International Journal of Obesity
Publisher: Springer Science and Business Media LLC
Published: 1999-03
Volume: 23
Issue: 3
Pages: 304-311
ISSN: 0307-0565 (ISSN-L)
1476-5497
DOI: 10.1038/sj.ijo.0800818
OpenAlex: W2005334239
Cited by: 468
References: 31
Citations by year: 2026: 7 · 2025: 11 · 2024: 10 · 2023: 12 · 2022: 7 · 2021: 10 · 2020: 10 · 2019: 7 · 2018: 12 · 2017: 12 · 2016: 17 · 2015: 22 · 2014: 18 · 2013: 26 · 2012: 25
FWCI: 4.67
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: International Journal of Obesity (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords: glucagon-like peptide-1, appetite, energy intake, obesity, hunger, gastric emptying, satiety, peptide YY, insulin, glucose, intravenous infusion
MeSH terms: Adult, Appetite, Blood Glucose, C-Peptide, Energy Intake, Double-Blind Method, Eating, Gastric Emptying, Glucagon, Humans, Hunger, Infusions, Intravenous, Insulin, Male, Obesity, Peptide Fragments, Protein Precursors, Body Mass Index, Cross-Over Studies, Peptide YY, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks